Biogen (BIIB) EBITDA Margin (2009 - 2026)
Biogen (BIIB) posted EBITDA Margin of 23.56% for Q2 2026, down 106.03% on a QoQ basis from 11.43% in Q1 2026, and down 2881.0% year-over-year from 0.85% in Q2 2025.
Powered by 
Analysis
Biogen (BIIB) EBITDA Margin (2009 - 2026) Analysis & Trends
Biogen has reported EBITDA Margin for 18 years, with the latest figure at 23.56% in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 2881.0% year-over-year to 23.56% in Q2 2026; TTM through Jun 2026 was 15.92%, a 933.0% decrease from a year earlier, with the FY2025 full-year figure at 8.57%, down 439.0% from the prior year.
- EBITDA Margin was 23.56% for Q2 2026 at Biogen, down from 11.43% in the prior quarter.
- The five-year high for EBITDA Margin was 35.94% in Q3 2022, with the low at 31.65% in Q3 2023.
- Average EBITDA Margin over 5 years is 0.63%, with a median of 4.0% recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 6759 bps in 2023, then soared 2404 bps in 2024.
- Over 5 years, EBITDA Margin stood at 17.29% in 2022, then tumbled by 69 bps to 5.35% in 2023, then slumped by 322 bps to 11.9% in 2024, then sank by 103 bps to 24.19% in 2025, then advanced by 3 bps to 23.56% in 2026.
- The last three EBITDA Margin figures came in at 23.56% (Q2 2026), 11.43% (Q1 2026), and 24.19% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | -0.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.56% |
| Mar 31, 2026 | -11.43% |
| Dec 31, 2025 | -24.19% |
| Sep 30, 2025 | -4.62% |
| Jun 30, 2025 | 5.25% |
| Mar 31, 2025 | -13.09% |
| Dec 31, 2024 | -11.90% |
| Sep 30, 2024 | -7.61% |
| Jun 30, 2024 | 6.19% |
| Mar 31, 2024 | -3.38% |
| Dec 31, 2023 | 5.35% |
| Sep 30, 2023 | -31.65% |
| Jun 30, 2023 | 4.70% |
| Mar 31, 2023 | -9.11% |
| Dec 31, 2022 | 17.29% |
| Sep 30, 2022 | 35.94% |
| Jun 30, 2022 | 30.34% |
| Mar 31, 2022 | 24.12% |
| Dec 31, 2021 | 21.48% |
| Sep 30, 2021 | 28.57% |